Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.

We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.

If you need assistance finding or assessing business development and/or partnership opportunities, contact us at

Current Projects

Seeking Parenteral & Ophthalmic Products for In-Licensing  
Posted on Jan 21, 2016


Lacerta Bio is seeking both parenteral and ophthalmic (topical) products for in-licensing on behalf of a US-based client.  Key criteria are: > Products which can be developed via the 505(b)(2) regulatory process in the US > No specific therapeutic area or indication > Injectable could be infusion, prefilled syringe, or related presentation > Ophthalmics are

  Read More»

Problem Solved: Novel mTOR 1/2 Inhibitor Available for Licensing  
Posted on Dec 04, 2017


Our client has a Preclinical, highly selective mTOR 1/2 inhibitor available for licensing. This compound is a truly selective inhibitor of both mTORC1 and mTORC2, without PI3K activity or toxicity. With an excellent projected safety profile & oral administration, a number of indications within and outside oncology are possible. For more information, contact us via email by clicking on the link

  Read More»

Novel Clinical-Stage Pain Candidates Available for Licensing  
Posted on Jul 11, 2017


  Our European client has developed a series of novel, patented salt forms of the most popular NSAIDS on the market (ibuprofen, naproxen, etc.). Clinical data demonstrates three important properties of these new compounds: Enhanced Safety – In multiple clinical studies, our client has shown that these novel salt forms have lower rates of severe

  Read More»

Our Latest Article

Book Review: What’s Your Bio Strategy? 
Posted on Dec 04, 2017



As a pharmaceutical scientist, the concept of “synthetic biology” sounds somewhat oxymoronic.

It’s true that our industry has been manipulating genes and cells to produce peptides, proteins, and other drugs/intermediates for decades.

But how about creating a cell line to make leather? Or clothing? Or building insulation?

Synthetic biology makes these ideas possible.

The authors take a very interesting approach. Instead of lecturing us on synthetic biology, they instead identify and interview 25-30 experts in their respective fields.

Some of the interviewees are familiar names, such as Craig Venter and George Church.

Importantly, the interview approach means a variety of subjects are covered in a very short, efficient manner.

If you’re unfamiliar with synthetic biology, then What’s Your Bio Strategy? by John Cumbers and Karl Schmieder is a great way to start.

One of the more interesting aspects of synthetic biology is the overlap between multiple disciplines, such as organism design, low-cost DNA synthesis, software, manufacturing, and others.

The final chapters on developing a bio strategy are also quite interesting.

You can pick up your own copy from Amazon or other fine book retailers.

Latest Posts

Review of 2017 and 2018 Predictions 
Posted on Dec 01, 2017

  What did we find interesting about 2017? What will happen in 2018? Our brief video summarizes our thoughts on the year that’s coming to a close, and also discusses what to keep an eye on in 2018.  

Only 100 Days Until #BIOEurope Spring… 
Posted on Nov 28, 2017

  As of this writing, there are 100 days until we’re wheels up and on our way to BIOEurope Spring in Amsterdam. Many believe it is too soon to think about a conference that is over three months away…or is it? This one gets complicated because of the intervening Winter Holidays and New Year. And

#BIOEurope: Schnell und Hektisch 
Posted on Nov 12, 2017

  It’s amazing how months of preparation for a conference are realized in 4-5 intense days.  From Sunday afternoon until the wee hours of Thursday morning, BIO-Europe in Berlin was jammed with 40 meetings, good meals, a few great receptions, a Buzz Session, two cigarettes, a few glasses of absinthe refreshment, and a new project or

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.